Skip to content
Screener

Operating Income at other companies

MBX Biosciences, Inc. logo
MBX Biosciences, Inc.MBX
-$27.27M-2.8%
Viking Therapeutics logo
Viking TherapeuticsVKTX
-$164.13M-196%
Crinetics Pharmaceuticals logo
Crinetics PharmaceuticalsCRNX
-$140.38M-26.0%
VAN
Vivani MedicalVANI
-$6.82M-4.0%
uniQure logo
uniQureQURE
-$52.2M-19.0%
MeiraGTx Holdings plc logo
MeiraGTx Holdings plcMGTX
-$40.82M+1.9%

Other financials

Income statement

See full
Revenue-
Gross profit-
Net income-$43.4M-4.8%
EPS (diluted)-$0.39+15.2%

Balance sheet

See full
Cash & equivalents$49.3M-15.1%
Total debt$5.3M-11.9%
Total equity$239.2M+42.5%
Total assets$264.6M+36.0%

Cash flow

See full
Operating cash flow-$31.4M-24.5%
CapEx$86.0K+330%
Free cash flow-$28.0M+52.6%

Valuation

See full
Market cap$2.7B+269%
Enterprise value$2.65B+291%

Profitability

See full
Gross margin100%+6.9pp
Operating margin-47,349.8%-47,409pp
Net margin-45,096.2%-45,152pp
FCF margin-39,826.7%-39,847pp

Returns & leverage

See full
Return on equity-74.7%-9.5pp
Debt / equity0.0×
Current ratio12.1×+3.4×

Where this comes from

Reported directly by Amylyx Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The source filing: Amylyx Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 7:04 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-336682
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Research and development$23,768$27,217$51,379$49,336
Selling, general and administrative21,92515,64038,09331,324
Total operating expenses45,69342,85789,47280,660
Loss from operations(45,693)(42,857)(89,472)(80,660)
Other income, net:
Interest income2,3231,9604,8934,191
Other expense, net(53)(546)(128)(881)
Total other income, net2,2701,4144,7653,310

Item 1. Financial Statements.

FAQ

What is Amylyx Pharmaceuticals, Inc.'s operating income?
Amylyx Pharmaceuticals, Inc. (AMLX) reported operating income of -$45.69M in Q2 2026.
How has Amylyx Pharmaceuticals, Inc.'s operating income changed year-over-year?
Amylyx Pharmaceuticals, Inc.'s operating income decreased by 6.6% year-over-year, from -$42.86M to -$45.69M.
What is the long-term trend for Amylyx Pharmaceuticals, Inc.'s operating income?
Over 4 years (2021 to 2025), Amylyx Pharmaceuticals, Inc.'s operating income has grown at a 16.7% compound annual growth rate (CAGR), from -$82.69M to -$153.29M.
What does operating income mean?
Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Ask your AI about Amylyx Pharmaceuticals, Inc.'s operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude